Glyport Inc

Xencor is a biotechnology company based in Monrovia, California, focused on developing innovative antibody therapeutics, particularly in the realm of bispecific antibodies. Utilizing its proprietary XmAb protein engineering platform, Xencor is advancing a diverse pipeline of drug candidates aimed at treating cancer and other serious diseases, with numerous programs currently in clinical testing. The company's unique approach allows for the creation of highly selective immune-modulators and targeted cancer therapies, enhancing treatment efficacy while improving stability and manufacturability. As an industry leader in bispecific antibodies, Xencor continues to forge partnerships and expand the therapeutic boundaries of antibody drugs. Generated from the website

The National Childhood Cancer Foundation, based in Arcadia, CA, is dedicated to ending childhood cancer through innovative, targeted research and funding initiatives. Their unique approach focuses on accelerating drug development for pediatric cancers with limited treatment options, ensuring that every child diagnosed with cancer has access to safe and effective therapies. With over $12 million awarded in research grants over the past five years, the foundation emphasizes translational research that quickly transitions breakthroughs from the laboratory to clinical trials. Their commitment to addressing unmet needs and involving leading experts in pediatric oncology enhances their ability to deliver measurable results in the fight against childhood cancer. Generated from the website

GeneFluidics, based in Duarte, CA, is a pioneering company that was established in 2000 with the aim of developing a cutting-edge testing system to enhance global health. By combining innovative bionano and microfluidic technologies, their revolutionary platform allows for complex tests that are typically conducted in laboratories by skilled technicians to be performed by anyone, anywhere. With a simple process that involves introducing a raw sample into a disposable cartridge and waiting for the results, GeneFluidics' platform offers fast, accurate, and user-friendly testing solutions. With a focus on nanotechnology-enabled analyte detection and microfluidic-based automated sample preparation, GeneFluidics' platform was initially conceived as part of a biodefense program. Over the years, the company has achieved significant milestones, including being selected as a finalist for the Antimicrobial Resistance Diagnostic (AMR) Challenge Step 2 and obtaining CE-IVD marking for their UtiMax uropathogen identification and antimicrobial susceptibility testing (AST). Additionally, GeneFluidics has received funding from the National Institute of Allergy and Infectious Diseases (NIAID) for the development and clinical validation of diagnostics, further solidifying their position as a leader in the field.Generated from the website